Business Wire

Registration Now Open for NPE2024: The Plastics Show

12.9.2023 19:34:00 EEST | Business Wire | Press release

Share

The Plastics Industry Association (PLASTICS) announced today that NPE2024: The Plastics Show registrations are now open through May 2024. NPE2024 will be the most impactful trade show of the year for all plastics industry sectors in the U.S. and globally, with more than 55,000 attendees expected.

Every three years, NPE offers the plastics industry a global platform to highlight innovation across a show floor with more than 1.1 million net square feet of exhibit space at the Orange County Convention Center in Orlando, Fla. Matt Seaholm, President and CEO of PLASTICS, highlighted that NPE2024 will return bigger and better than ever, “We look forward to welcoming our industry back to NPE2024: The Plastics Show next May. The plastic industry serves a critical and sustainable role in modern life; this show will be a testament to that.”

“With sustainability at the center of everything produced at the show, attendees will witness new technologies and significant education opportunities to push us toward a more circular economy and help our industry continue to grow,” said Seaholm.

NPE2024 returns, with the theme Made for You, where attendees are front and center of all experiences happening at the show. The event, held May 6-10, 2024, will offer opportunities for everyone in the industry, even those just starting their career. Some notable experiences at NPE2024 include:

  • Six technology zones with 2,000+ exhibitors showcasing their latest products and services
  • More than 100 speaker presentations on trending topics that foster innovation, drive circularity and exemplify collaboration
  • The brand-new NPE Circularity Hub where attendees will experience the plastics circular economy, from raw materials to go-to market consumer products
  • Influential women in the plastics industry will share their success stories with those attending the Women in Plastics Breakfast
  • More than 355 first-time exhibitors bringing to NPE2024 new products and perspectives
  • The inaugural NPE Opening Night Party featuring the band Pop Rocks, games, food and drinks

NPE2024 attendees will gain exclusive access to the entire plastics supply chain, including machinery and equipment, raw materials, recycling and sustainability, automation and robotics, 3D and 4D printing, inspection, design, and more. NPE exhibitors service vital markets such as automotive, consumer products, recycling, packaging, medical, and building and construction.

Important dates to remember if planning on attending NPE2024:

  • Attendee registration for NPE2024 opens on Tuesday, September 12, 2023
  • Registration for the hotel room block also begins on Tuesday, September 12, 2023
  • NPE2024 event dates are May 6-10, 2024, at the Orange County Convention Center in Orlando, Fla.

Tickets for NPE2024 range from $100 - $600; prices vary depending on early bird, advanced and on-site sales. Add-ons to the NPE Opening Night Party, Women in Plastics Breakfast, Seminarios Latinoamericanos, and 3D Printing for Plastic Processors are also available on a first-come, first-served basis, inquire for details.

“NPE2024 is at the forefront of the plastics future. If you want to further your career, grow your company or keep up with new trends and solutions, NPE2024 is where you need to be in May 2024. We encourage you to register today and start planning and customizing your experience as we continue to reveal all the exciting things happening at the event,” concluded Steve London, NPE2024 Committee Chair.

For more information about NPE2024: The Plastics Show and to register, visit: NPE.org.

The Plastics Industry Association (PLASTICS) is the only organization that supports the entire plastics supply chain, including Equipment Suppliers, Material Suppliers, Processors, and Recyclers, representing over one million workers in our $548 billion U.S. industry. PLASTICS advances the priorities of our members who are dedicated to investing in technologies that improve capabilities and advances in recycling and sustainability and providing essential products that allow for the protection and safety of our lives. Since 1937, PLASTICS has been working to make its members, and the seventh largest U.S. manufacturing industry, more globally competitive while supporting circularity through educational initiatives, industry-leading insights and events, convening opportunities and policy advocacy, including the largest plastics trade show in the Americas, NPE2024: The Plastics Show.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Elizabeth Domenech pr@npe.org

Camille Gallo cgallo@plasticsindustry.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye